Your Medications Aren't Working. Your Genes May Be Why.

CYP2D6 is your liver’s workhorse enzyme. It breaks down antidepressants, opioid painkillers, beta-blockers for blood pressure, and many others. When this enzyme works normally, you take a standard dose and your body converts it into active drug at a predictable rate.

Variants like *2, *4, *10, and *17 impair this enzyme’s function. Roughly 7-10% of people with European ancestry carry variants that make them poor metabolizers. Poor metabolizers accumulate drug levels that should take hours to build up, instead building up within minutes, triggering side effects from a standard dose.

You might experience dizziness, nausea, tremors, or emotional numbness on a dose that should be helping. Or you might feel nothing because the drug is being cleared so slowly that it never reaches therapeutic levels in your brain. Either way, your doctor sees treatment failure and reaches for a higher dose, which only worsens the problem.

CYP2C19 has a particularly dangerous job: it activates clopidogrel, a drug given after heart attacks and stents to prevent blood clots. If you carry *2 or *3 variants, you are a poor metabolizer. The drug cannot activate in your body, leaving you without antiplatelet protection when clot formation could be fatal.

Roughly 2-15% of the population carries poor metabolizer variants, depending on ancestry. Poor metabolizers on clopidogrel get zero antiplatelet benefit despite taking the medication daily, creating a false sense of protection that masks real clot risk.

This isn’t a side effect. It’s a complete failure of the drug to work. Your cardiologist has no way of knowing unless your DNA is tested. You feel fine, taking your medication on schedule, and your clot risk remains unchanged.

CYP2C9 breaks down warfarin, one of the oldest and most powerful blood thinning medications. It also metabolizes NSAIDs like ibuprofen and naproxen, and cholesterol medications. The standard warfarin dose is calculated assuming normal CYP2C9 function.

Variants *2 and *3 reduce enzyme activity. Roughly 5-10% of people with European ancestry carry these variants. Poor metabolizers on standard warfarin doses accumulate the drug to dangerous levels, creating bleeding risk from doses that should be safe.

You might wake up bruising easily, seeing blood in your urine, or noticing bleeding gums. These aren’t side effects to tolerate. They’re signs that your warfarin dose is too high for your genetics. Without pharmacogenomics guidance, your doctor will assume the dose is fine and you’ll continue accumulating risk.

SLCO1B1 is not an enzyme. It’s a transporter protein on your liver cells that pulls statins (cholesterol drugs) inside, where they can work. Without this transporter, statins accumulate in your bloodstream instead of concentrating in your liver, where they’re needed.

The *5 variant, found in roughly 15% of the population, reduces transporter function. Carriers of SLCO1B1 variants have higher systemic statin levels, dramatically increasing the risk of muscle pain and breakdown (statin myopathy) on standard doses.

You might develop muscle soreness that feels like you’ve overexercised, even when you’re resting. Your doctor might attribute it to aging or overtraining, not realizing your statin dose is accumulating to dangerous levels in your bloodstream. Simvastatin is particularly problematic; other statins are safer.

VKORC1 encodes vitamin K epoxide reductase, the exact protein that warfarin blocks. The VKORC1 -1639G>A variant changes how sensitive your enzyme is to warfarin’s blocking effect. This is not about how fast you metabolize warfarin. It’s about how much warfarin it takes to block your vitamin K recycling.

The A allele is carried by roughly 40% of people with European ancestry. People with the A allele have reduced vitamin K recycling capacity, making them hypersensitive to warfarin; standard doses that work for others cause excessive bleeding in them.

You might be on a dose your neighbor takes safely and still experience bruising, nosebleeds, or bleeding in your urine. Your INR climbs faster on lower doses. Your doctor might assume your metabolism is unusual without realizing your VKORC1 variant means you need fundamentally lower doses.

MTHFR converts dietary folate into the active methylfolate form your cells need for DNA synthesis and repair. Several medications, including methotrexate, work by interfering with folate-dependent pathways. If your MTHFR function is impaired, you’re operating with a compromised methylation system.

The C677T variant is carried by roughly 40% of people with European ancestry. C677T carriers have 40-70% reduced MTHFR enzyme activity, impairing the folate-dependent pathways that some drugs target.

If you’re on methotrexate for rheumatoid arthritis, lupus, or cancer, impaired MTHFR function can reduce drug efficacy or increase side effects because your cells’ folate metabolism is already struggling. You might experience worse inflammation response, increased toxicity, or unpredictable drug behavior compared to people with normal MTHFR function.